Articles

Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
No Increased Risk of Heart Failure Hospitalization or Major Cardiovascular Events Observed With Liraglutide in Patients With or Without a History of New York Heart Association Class I Heart Failure: Results From the LEADER Trial
Empagliflozin Reduces Mortality and Hospitalization For Heart Failure in Patients With or Without a History of Myocardial Infarction or Stroke at Baseline
CVD-REAL 2: SGLT-2 Inhibitors Associated With Lower Cardiovascular Risk Versus Other Glucose-Lowering Drugs
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab - ODYSSEY OUTCOMES
Canagliflozin Cardiovascular Assessment Study - CANVAS
Effect of liraglutide on cardiovascular outcomes in elderly patients in the leader trial
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

Pages